TREM2 and Parkinson’s Disease
Open accessThe DOI matches its OpenAlex record.
Abstract
The finding of a rare non-synonymous variant in TREM2 (p.R47H, rs75932628-T) confers risk for Alzheimer's disease (AD) (odds ratio 2 to 5),1, 2 and the finding that rare variants in other AD-related genes confer risk of several other neurodegenerative diseases,3 prompted us to ask whether R47H confers risk of Parkinson Disease. Several other observations supported our hypothesis that TREM2 variation may confer susceptibility to Parkinson Disease. TREM2 is expressed mainly on microglia in the central nervous system and seems to mediate the phagocytosis of apoptotic neurons through TREM2 ligation4. Microgliosis has been implicated in the pathogenesis of Parkinson’s disease (PD), a neurological disorder characterized by degeneration of dopaminergic neurons in the substantia nigra (SN) pars compacta. Dopaminergic neurons express ligands that interact directly with TREM24 and, TREM2 mRNA levels in the SN are the second highest among all brain regions1. In addition, pathological findings of TREM2 variant carriers have shown the presence of abundant Lewy-bodies1, the hallmark of PD. We directly genotyped rs75932628, encoding the R47H variant, in 478 PD patients and 837 healthy individuals from the Washington University in Saint Louis Movement Disorder Clinic5 as well as in 654 PD patients and 550 controls from the Memory Disorders Unit, Clinica Universidad de Navarra, School of Medicine (Pamplona, Spain)2. PD diagnosis was established according to the UK Brain Bank criteria. We found three p.R47H heterozygous carriers among the US PD cases and six among the Spanish PD cases, but in none of the screened controls (Table 1). The p.R47H variant is associated with PD in both the US (p=0.02) and in the Spanish sample (p=0.02). The combined analysis confirmed the association p.R47H variant with PD (p=4.7 × 10−3). These results suggest that the p.R47H variant not only increases risk for AD but for PD as well. Table 1 Association between the rs75932628-T Variant and Parkinson's Disease in two samples with different genetic background
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357
Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease
Cruchaga, C., Karch, C. M., Jin, S. C., Benitez, B. A., Cai, Y., Guerreiro, R., Harari, O., Norton, J., Budde, J., Bertelsen, S., et al. (2014) · Nature · doi:10.1038/nature12825 · Cited by 461
TREM2 in Neurodegenerative Diseases
Jay, T. R., von Saucken, V. E., & Landreth, G. E. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0197-5 · Cited by 427
Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status
Piccio, L., Deming, Y., Del-Águila, J. L., Ghezzi, L., Holtzman, D. M., Fagan, A. M., Fenoglio, C., Galimberti, D., Borroni, B., & Cruchaga, C. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1533-5 · Cited by 337
Self-citationCoding variants in TREM2 increase risk for Alzheimer's disease
Jin, S. C., Benitez, B. A., Karch, C. M., Cooper, B., Skorupa, T., Carrell, D., Norton, J. B., Hsu, S., Harari, O., Cai, Y., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu277 · Cited by 314
Metadata
- Authors
- Benítez, B. A., & Cruchaga, C.
- Venue
- PubMed Central
- Publisher
- National Institutes of Health
- Published
- 2013-10-17
- Volume
- 369
- Issue
- 16
- Pages
- 1567
- OpenAlex
- W1557189729
- Cited by
- 65
- References
- 0
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TREM2 and Parkinson’s Disease. https://app.cochat.ai/papers/10.1056/nejmc1306509%23sa4
- The paper
- Benítez, B. A., & Cruchaga, C. (2013). TREM2 and Parkinson’s Disease. PubMed Central. https://doi.org/10.1056/nejmc1306509%23sa4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.